Kioxia today announced an update to its KIOXIA AiSAQ software, allowing balance specific workloads in RAG systems without hardware modifications.

The mRuby2 biomarker was meant to label all transduced cells. The secondary treatment vector was AAV9-CAG-DIO-NeuroD1-T2A-mRuby2, which was delivered at a concentration of 1.0E13 GC/mL (Figure 1C).